NUVASIVE INC (NUVA) Stock Price, Quote, News and Overview
NASDAQ:NUVA - Nasdaq - US6707041058 - Common Stock - Currency: USD
NUVA Quote, Performance and Key Statistics
39.75
-0.91 (-2.24%)
The current stock price of NUVA is 39.75 USD. In the past month the price decreased by -0.62%. In the past year, price decreased by -8.3%.
NUVA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About NUVA
Company Profile
NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. The company is headquartered in San Diego, California and currently employs 3,000 full-time employees. The company went IPO on 2004-05-13. The firm is focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company offers a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. In addition, it develops and sells magnetically adjustable implant systems for the spine and specialized orthopedic procedures. The company also designs and sell expandable growing rod implant systems for the treatment of early-onset scoliosis that can be non-invasively lengthened after implantation with incremental adjustments via an external remote controller using magnetic technology called MAGneticExternal Control (MAGEC). The company operates in more than 50 countries serving surgeons, hospitals, and patients.
Company Info
NUVASIVE INC
7475 Lusk Blvd
San Diego CALIFORNIA 92121 US
CEO: J. Christopher Barry
Employees: 3000
Company Website: https://www.nuvasive.com/
Phone: 18589091800.0
NUVASIVE INC / NUVA FAQ
What is the stock price of NUVASIVE INC today?
The current stock price of NUVA is 39.75 USD. The price decreased by -2.24% in the last trading session.
What is the ticker symbol for NUVASIVE INC stock?
The exchange symbol of NUVASIVE INC is NUVA and it is listed on the Nasdaq exchange.
On which exchange is NUVA stock listed?
NUVA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NUVASIVE INC stock?
22 analysts have analysed NUVA and the average price target is 50.72 USD. This implies a price increase of 27.6% is expected in the next year compared to the current price of 39.75. Check the NUVASIVE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NUVASIVE INC worth?
NUVASIVE INC (NUVA) has a market capitalization of 2.08B USD. This makes NUVA a Mid Cap stock.
How many employees does NUVASIVE INC have?
NUVASIVE INC (NUVA) currently has 3000 employees.
What are the support and resistance levels for NUVASIVE INC (NUVA) stock?
NUVASIVE INC (NUVA) has a support level at 39.5 and a resistance level at 41.59. Check the full technical report for a detailed analysis of NUVA support and resistance levels.
Is NUVASIVE INC (NUVA) expected to grow?
The Revenue of NUVASIVE INC (NUVA) is expected to grow by 6.01% in the next year. Check the estimates tab for more information on the NUVA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NUVASIVE INC (NUVA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NUVA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NUVA, evaluating the profitability, health, valuation and growth aspects
- NUVASIVE INC (NUVA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NUVASIVE INC (NUVA) Sales and EPS estimates to see what analysts future expectations are.
- NUVASIVE INC (NUVA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NUVASIVE INC (NUVA) Insider and Institutional Ownership to learn about the owners and their transactions.
- NUVASIVE INC (NUVA) Stock Chart to make your own analysis
- NUVASIVE INC (NUVA) Latest news and press-releases to stay up to date.
Does NUVASIVE INC (NUVA) stock pay dividends?
NUVA does not pay a dividend.
When does NUVASIVE INC (NUVA) report earnings?
NUVASIVE INC (NUVA) will report earnings on 2023-11-07, after the market close.
What is the Price/Earnings (PE) ratio of NUVASIVE INC (NUVA)?
The PE ratio for NUVASIVE INC (NUVA) is 19.88. This is based on the reported non-GAAP earnings per share of 2 and the current share price of 39.75 USD. Check the full fundamental report for a full analysis of the valuation metrics for NUVA.
NUVA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NUVA. When comparing the yearly performance of all stocks, NUVA turns out to be only a medium performer in the overall market: it outperformed 43.5% of all stocks.
NUVA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NUVA. NUVA has a medium profitability rating, but doesn't score so well on its financial health evaluation.
NUVA Financial Highlights
Over the last trailing twelve months NUVA reported a non-GAAP Earnings per Share(EPS) of 2. The EPS increased by 15.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.32% | ||
| ROA | 1.36% | ||
| ROE | 3.19% | ||
| Debt/Equity | 0.89 |
NUVA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 71% to NUVA. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 13.97% and a revenue growth 6.01% for NUVA